In a notable display of resilience, shares of Tilray defied broader market weakness to post gains, driven by news of an exclusive new alliance. The cannabis-focused conglomerate has entered a pivotal partnership with brewing titan Carlsberg for the crucial United States market. This strategic move aims to revitalize Tilray’s recently underperforming beverage division.
A Strategic Pivot for the Beverage Segment
The multi-year agreement, effective January 1, 2027, grants Tilray the rights to produce and distribute Carlsberg’s portfolio in the US. Key brands included are Carlsberg Elephant and Kronenbourg 1664 Blanc. The company intends to leverage its established national distribution network and existing infrastructure to manufacture these European premium beers locally.
This expansion is designed to bolster shelf presence and accelerate revenue growth within the world’s second-largest beer market. The deal also contains a provision for a five-year extension, contingent upon meeting specific performance milestones.
Financial Context: A Segment in Need of a Boost
The timing of this collaboration is critical. For its second fiscal quarter of 2026, Tilray reported record revenue of $217.5 million and more than halved its net loss per share to $0.41. However, the beverage unit specifically experienced a 20% decline in sales, falling to $50.1 million.
Should investors sell immediately? Or is it worth buying Tilray?
The Carlsberg partnership directly targets this soft spot in the premium segment. In contrast, the core cannabis business remained stable, posting a 3% revenue increase. Notably, the international cannabis segment—fueled by developments in Germany and Europe—saw substantial growth of 112% on a pro-forma basis excluding Australia.
Investor Sentiment and Analyst Perspective
The market responded positively to the strategic announcement. Tilray’s stock climbed to $7.99, registering a 2.04% gain on a day when both the S&P 500 and Nasdaq closed in negative territory. Despite this uptick, the shares remain under pressure on a longer-term view, down approximately 16% year-to-date.
Market observers maintain a predominantly cautious stance. The average analyst price target for Tilray stands at $13.33, with the majority of experts currently rating the stock as a “Hold.”
The Path Forward and Upcoming Catalyst
Investors’ next key focus is April 14, 2026, when Tilray is scheduled to release its subsequent quarterly results. With the Carlsberg agreement not commencing until 2027, short-term attention will center on the company’s ability to confirm its adjusted EBITDA guidance of $62 to $72 million and demonstrate progress on ongoing cost-saving initiatives. Management must prove it can bridge the gap until the new partnership begins by delivering operational growth.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from February 27 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 27.
Tilray: Buy or sell? Read more here...
